Early HR+

Clinical insights on early-stage HR-positive breast cancer, focusing on risk stratification and evolving adjuvant treatment strategies, including endocrine therapy and CDK4/6 inhibitors to guide clinical decision-making.

Ep. 4: Early-Stage HR-Positive Breast Cancer: Managing CDK4/6 Inhibitor Sequencing

Sara Hurvitz, MD, FACP, Sherry Shen, MD, Eleanora Teplinsky, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 3: Liver Toxicity, Risk Stratification, and Personalized Adjuvant Therapy in Early-Stage HR-Positive Disease

Sara Hurvitz, MD, FACP, Sherry Shen, MD, Eleanora Teplinsky, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 2: Practical Guidance for Ribociclib and Abemaciclib in the Adjuvant Setting

Sara Hurvitz, MD, FACP, Sherry Shen, MD, Eleanora Teplinsky, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 1: Adjuvant Ribociclib in Early-Stage HR-Positive Breast Cancer: Clinical Insights

Sara Hurvitz, MD, FACP, Sherry Shen, MD, Eleanora Teplinsky, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Adjuvant Ribociclib and Abemaciclib in Early HR+ Breast Cancer (Full Video)

Eleanora Teplinsky, MD, Sara Hurvitz, MD, FACP, Sherry Shen, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD